GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Lpath Inc (LPTN) [hlAlert]

Rating:
Buy LPTN
down 76.66 %

Lpath, Inc. (LPTN) rated Buy with price target $8 by Morgan Joseph

Posted on: Thursday,  Sep 8, 2011  1:25 PM ET by Morgan Joseph

Morgan Joseph rated Buy Lpath, Inc. (NASDAQ: LPTN) on 09/08/2011, when the stock price was $0.90. Since
then, Lpath, Inc. has lost 76.67% as of 01/22/2016's recent price of $0.21.
If you would have followed this Morgan Joseph's recommendation on LPTN, you would have lost 76.66% of your investment in 1597 days.

Lpath, Inc. is a biotechnology company focused on the discovery and development of lipidomic-based therapeutics, an emerging field of medical science whereby bioactive lipids are targeted to treat human diseases. The Company?s product candidate, ASONEP, is the systemic formulation of sonepcizumab, a humanized monoclonal antibody (mAb) against sphingosine-1-phosphate (S1P). ASONEP has demonstrated compelling results in preclinical studies against multiple forms of cancers and against multiple sclerosis. The Company?s second product candidate is iSONEP, the ocular formulation of Sonepcizumab. iSONEP has demonstrated multiple mechanisms of action in ocular models of disease, including anti-angiogenesis, anti-inflammatory and anti-vascular permeability. The Company's third product candidate, Lpathomab, is a monoclonal antibody against lysophosphatidic acid (LPA).

Morgan Joseph is committed to providing timely, objective and actionable investment advice on the companies and securities we follow. Our team of equity analysts covers a growing universe of stock issues across a broad range of industry sectors. As a middle market-focused firm, our approach is not to publish research on as many companies as possible within a number of industry sectors. Rather, our research analysts distinguish themselves by zeroing in on quality companies with growth prospects or which present special situations. These companies often lack a research following. This enables our analysts to provide insight to investors in companies that are not well understood nor fairly valued.
as of 1/1/0001
1 Week   
1 Month   
3 Months   
1 YTD   

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy